# Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805

> **NCT01424540** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 20 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** GSK2336805 150mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01424540
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-01
- **Primary completion:** 2011-10-03
- **Final completion:** 2011-10-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01424540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01424540, "Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01424540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*